The NICHD Fetal Growth Study: Twin Gestations

Status Completed

Clinical Trial Summary

Normal growth and development of twins are important for the long-term health of the children. The purpose of this study was to empirically define the trajectory of fetal growth in dichorionic twins using longitudinal two-dimensional ultrasonography and to compare the fetal growth trajectories for dichorionic twins with those based on a growth standard developed by our group for singletons. This knowledge may lead to interventions that could minimize or prevent pregnancy and newborn health problems in the future.

Clinical Trial Description

A prospective cohort of 171 women with twin gestations was recruited from eight U.S. sites from 2012 to 2013. After an initial sonogram at 11w0d-13w6d where dichorionicity was confirmed, women were randomized to one of two serial ultrasonology schedules. Ultrasound measurements at each follow-up visit included standard fetal biometrics ((BPD, HC, AC, FL); estimated fetal weight was calculated using a Hadlock formula. Growth curves and percentiles were estimated using linear mixed models with cubic splines. Percentiles were compared statistically at each gestational week between the twins and 1,731 singletons in the Fetal Growth Studies-Singletons cohort.

In addition to 2-D ultrasound measures for analyzing fetal growth, this study recorded maternal anthropometrics and a brief interview to capture changes in health status, stress and depression, and physical activity at each follow-up visit. Four blood draws at baseline and at targeted gestational ages for the eventual identification of biomarkers indicative of fetal growth were collected. After delivery, neonatal anthropometric measures were assessed for each twin, placental biospecimens were collected, and select information about the obstetrical course and newborn status were abstracted from medical charts. These exposures and outcomes provide opportunities to further compare singleton and twin gestations with respect to maternal biomarkers of fetal growth, well-being and maternal nutritional status using banked biospecimens to determine if the biomarkers ranges established for singletons are applicable to twin gestations.

Biospecimen Description:

- Maternal blood sample (serum, plasma, white blood cells, red blood cells and PAXgene RNA) at enrollment, 1st, 3rd, 5th follow-up visits, and delivery

- Cord blood and placentas for consenting women collected at delivery

- Placenta sample or buccal swab (determining zygosity by DNA probe for same sex pairs), collected at delivery ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01369940
Study type	Observational
Source	National Institutes of Health Clinical Center (CC)
Contact
Status	Completed
Phase	N/A
Start date	May 29, 2011
Completion date	September 30, 2014

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05934318` - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)	N/A
Recruiting	`NCT05601375` - Speckle Tracking Echocardiography in Infants, Prenatally and Postnatally
Recruiting	`NCT03662178` - Investigating the Structured Use of Ultrasound Scanning for Fetal Growth
Completed	`NCT05059093` - Developing and Testing AI Models for Fetal Biometry and Amniotic Volume Assessment in Fetal Ultrasound Scans.
Completed	`NCT03067298` - Prediction of Preeclampsia and Other Pregnancy Complications Following Combined Iterative Screening
Recruiting	`NCT01981824` - Prediction of Growth Restricted Fetuses Using Femur Length to Mid-thigh Circumference Ratio: A Case-control Study	N/A
Recruiting	`NCT04215107` - Fetal Distribution of Feto-placental Blood Flow Related to Placental Nutrient Transport and Maternal Food Intake	N/A
Completed	`NCT02189148` - First-trimester Prediction of Preeclampsia
Terminated	`NCT04084990` - Sleep Apnea and Fetal Growth Restriction	Phase 3
Recruiting	`NCT04051567` - Low-dose Aspirin for Prevention of Adverse Pregnancy Outcomes in Twin Pregnancies	Phase 4
Recruiting	`NCT04394611` - Metals and in Fetal Growth Restriction
Not yet recruiting	`NCT03121196` - Social Deprivation and Pregnancy	N/A
Recruiting	`NCT03177824` - Sildenafil Citrate for Treatment of Growth-restricted Fetuses	Phase 3
Completed	`NCT02379832` - Pre-Eclampsia And Growth Restriction: a Longitudinal Study
Completed	`NCT02379494` - First Trimester Prediction of Preeclampsia and Fetal Growth Restriction	N/A
Completed	`NCT03046355` - Timing of Delivery in Fetal Growth Restriction of Uncomplicated Women	N/A
Not yet recruiting	`NCT05848869` - Prostaglandins Versus Trans-cervical Balloon for Induction of Labor in Fetal Growth Restriction	N/A
Recruiting	`NCT04438668` - Evaluation of the Safety and Performance of Centaflow	N/A
Recruiting	`NCT05423665` - Speckle Tracking Echocardiography as a Tool for Early Diagnosis of Impaired Fetal Growth Twin Pregnancies
Not yet recruiting	`NCT06343051` - USCOM in Newly Diagnosed FGR Cases

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.